Pain Therapeutics, Inc
Company History
. (Public, NASDAQ:PTIE) is a biopharmaceutical company that produces drugs. It is found in San Mateo, California and is approximately 30,700 square feet in space. The company has 201,000 private-sector jobs.
Platforms, products, accreditations
Pain Therapeutics is rising up with a new production of painkillers known as opioid. These are products generated from the plant known as poppy. With the help of technology, the company reformulates opioid medicines such as morphine into innovative painkillers .The business has four painkillers of opioids in stage II medical trials and believes that their medicines relief pain. In addition, they belief their drugs have low unfavorable side effects unlike the existing opioid painkillers.
Main Competitors
The main competitors of the company include pipeline products such as pre-clinical, clinical and marketed pipeline of products. It has 42.95M shares and the market cap is 379.22M. The price of its products ranges from 8.65-8.99 and its financial value changes slightly making a profit of 0.91 percentages. By next year, sales may increase by 174.80 percent and earnings by 83.80 percent per year. The company sells approximately 8.85 within a moving average of 7.05 per 50 days, and mostly 96 percent purchase the products (Meerteen, 2011). The global acute pain therapeutics market was valued at ten billion in 2010. The slow growth is attributed to a low treatment seeking behavior, disease awareness and usage of generic drugs.
There is more than one product evolving constantly with latest features and services in the pipeline. Biofind rumor Mill Company has latest gossips and biotech news about different business activities. The company is collaborating with other companies within the industry especially the extensive directory of companies. This company collaborates with other companies in order to target the market of biotech professionals. The company aims to collaborate with other established online services in order to develop and advance the Biofind range of products (Lovy, 2011).
Biofind Rumor Mill became a publicly traded company on March 1999, as one of the most flourishing and greatest growing community web sites. It serves the rapidly increasing biotechnology, pharmaceuticals and diagnostics firms with news, rumors, business advertisings, employments and events of the industry. The company was founded eleven years ago and it has greatly served the biotechnology industry and other business companies. The key events in the company’s life since the IPO are the creation of Bio portfolio strategies in life science, medical devices and pharmaceuticals conferences through advertisement to widen the business industry. This have affected the share price especially in business and science events leading to problems such as unemployment, high costs of products and heavy taxes on the bonuses of the bankers (Mill, 2010).
Performance
There have been other stock offerings and the company had to share the prices. The company chooses the right time for an IPO because it acquires support from an underwriting industry that enables it to establish the kind of security preferred. The stock prices of the company will not rise until the effect on earnings from the losses realized. It will still dominate the portfolio in sales and profits, making the company to achieve efficient market. In addition, the company secures the cost that might arise in the future thus through using an IPO costs may reduce in the near future. Lastly, the company’s stock market will not decline, but rather expand their brand sales in the emerging markets (Nemethy, 2011).
Figure 1: Chat showing stock price of Pain Therapeutics, Inc. (PTIE) using IPO
The company was motivated into public offerings by other competitors thus had to look for a solution of going to public offerings due to the fear of making losses. They also wanted to avoid persuasion from other investors. The company’s strategies have not changed since going public because they still use their IPO in order to maximize profits and expand their products. The company still uses their own strategies in order to maintain their business and to overcome competitors in the market. Figure 1 below shows a chart and summary of business performance and stock prices since the use of an IPO (Mill, 2010).
References
Grassl, B. (2006). The Sarbanes-Oxley Act of 2002: A dealbreaker for IPO-exit strategies. Wellington: VictoriaUniversity of Wellington.
Lovy, H. (2011, 15 March). Making sense of the Alzheimer’s drug pipeline. Fierce Biotech
Research. Retrieved from http://www.fiercebiotech.com/news
Meerten, V. (2011). Pain Therapeutics’ Opium for the Masses. Retrieved
from http://seekingalpha.com/article/260079-pain-therapeutics-opium-for-the-masses.
Mill, R (2010).Biofind an insight for the biotech industry. Retrieved from
http://www.biofind.com/
Nemethy, L. (2011). Business exit planning: Options, value enhancement, and transaction
management for business owners. Hoboken, NJ: John Wiley & Sons.
Last Completed Projects
| topic title | academic level | Writer | delivered |
|---|